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Osteoarthritis (OA) is a degenerative disease of joint 
cartilage that occurs in a large proportion of elderly people. 
In  OA,  cartilage  matrix  is  lost  gradually,  which  eventu-
ally devastates functional joints. Joint pain and movement 
limitation are the primary symptoms associated with this 
disease. Contributing to OA pathogenesis, cartilage dam-
age  induces  disease-related  factors,  including  proteolytic 
enzymes of the matrix metalloproteinase (MMPs) and ag-
grecanase  families,  cytokines,  chemokines  and  growth 
factors1–7.  However,  causal  genes,  the  molecular  biologi-
cal background and the signal pathways of this disease are 
largely unknown. There are a number of OA models, such as 
anterior surgical ligament transection (ACLT), medial men-
iscectomy1,7–9, collagenase injection10, extracellular matrix 
loss11,12, impact-induced trauma13, monoiodoacetate (MIA) 
injection14–16, the age-associated spontaneous OA-like mod-
el17,18 and STR/OrtCrlj mice19,20. It is essential that these OA 
models are investigated in creating new drugs for OA dis-
ease and for each different stage in drug development, such 
as the screening and preclinical stages. However, each of 
these animal models likely reflects only a subset of cases 
due to the heterogeneity of human OA. Moreover, though 
human OA and these models actually have some common 
pathological  appearances,  analyses  of  histopathological 
similarities between human OA and these animal models 
have just started. Recently, it was reported that VEGF and 
its receptors are expressed in human OA accompanying the 
progression of this disease, and this suggested the possibil-
ity that a mechanism via VEGF is implicated for destruction 
of OA articular cartilage21.
In the present study, we examined the expression of 
VEGF in the articular cartilage in OA-like models; rat me-
dial meniscectomy, rat MIA injection and guinea pig age-
associated spontaneous joint cartilage destruction. We then 
found that the immunoreactivity of VEGF in the cartilage 
commonly enhances with the degree of cartilage destruc-
tion and reparation in these models of rodents.
We used two OA-like models of the rat: medial menis-
cectomy and MIA injection. Moreover, an aged guinea pig 
model showing spontaneous joint cartilage destruction was 
also investigated. This is abbreviated here as the “SPOA 
model.” In the medial meniscectomy model, twelve male 
Fischer rats (F344/DuCrlCrlj, 12 weeks old) were used, and 
the surgery was carried out at the facilities of Charles River 
Laboratories Japan Inc. (Yokohama, Japan). At 1, 2 and 5 
weeks after medial meniscectomy and sham operation (n = 
3 per group) as a control, rats were killed under anesthesia 
by isoflurane inhalation, and the right knee joints were re-
moved for pathological evaluation. In the MIA model, four 
male Lewis rats (8 weeks old) were used and treated with a 
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single intra-articular injection of 0.3 mg MIA (Wako Pure 
Chemical Industries, Ltd., Osaka, Japan). At 1 week after 
MIA or saline injection (n = 2 per group) as a control, rats 
were killed under anesthesia, and the right knee joints were 
removed for pathological evaluation. In the SPOA model, 
eight  Hartley  guinea  pigs  purchased  from  Charles  River 
Laboratories Japan Inc. were used at 16 months of age and 
10 weeks age as control (n = 4 per group), and their joints 
were examined. All animal experiments were in accordance 
with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals and were approved in advance 
by the Committee of Animal Experiments in Research Lab-
oratories of Mitsubishi Tanabe Pharma Corporation.
Knee joints in the three models were fixed in 10% neu-
tralized buffered formalin, decalcified with buffered EDTA 
(10% ethylenediaminetetraacetic acid, pH 7.4), transected 
in the frontal or sagittal plane and embedded in paraffin. 
The sections included the tibial plateau and femoral con-
dyle and were stained with safranin O or toluidine blue and 
evaluated for cartilage damage and osteophyte formation. 
Immunohistochemistry was employed to assess expression 
and localization of VEGF according to the histopathological 
progress of damage/repair of the articular cartilage. Tissue 
sections were incubated overnight at 4 °C with anti-VEGF 
(A-20) rabbit polyclonal antibody (Santa Cruz Biotechnolo-
gy Inc., Santa Cruz, CA, USA) followed by horseradish per-
oxidase-labeled goat antibody against rabbit IgG (Nichirei, 
Tokyo, Japan) and visualized with 3.3’-diaminobenzidine.
Initially, histopathological changes and VEGF immuno-
histochemistry were examined in the articular cartilage of the 
tibial medial plateau in the rat medial meniscectomy model. 
A knee joint from a sham-operated animal used as a control 
is depicted in Fig. 1, panels A and B. One week after medial 
meniscectomy, the articular cartilage showed fibrillation, loss 
and degeneration of chondrocytes (Fig. 1C). Two weeks af-
ter the surgery, a migrational response of the perichondrium 
and initial osteophyte formation were seen (Fig. 1E). More-
over, osteophyte development and reorganization of the re-
generative articular cartilage were seen at 5 weeks after sur-
gery (Fig. 1G). Expression of VEGF in the articular cartilage 
was not detected in normal rats and the animals studied one 
week after surgery (Fig. 1B, D). Two weeks after the surgery, 
VEGF was observed in the perichondrium and regenerative 
or hypertrophic chondrocytes (Fig. 1F). The stain intensity of 
VEGF became obvious as the chondrocytes in the osteophyte 
area increased at 5 weeks after surgery (Fig. 1H).
Histopathological  changes  and  VEGF  immunohisto-
chemistry were then examined in the articular cartilage in 
rats of the MIA injection model. A knee joint from a saline-
injected animal as a control is depicted in Fig. 2, panels A 
and B. At 1 week after MIA injection, loss and degeneration 
of chondrocytes and a reduction of safranin O-positive pro-
teoglycan staining were observed in the articular cartilage 
without osteophyte formation (Fig. 2C, 2E). Although ex-
pression of VEGF was not detected in the articular cartilage 
of normal rats (Fig. 2B), some regenerative or hypertrophic 
chondrocytes showed positive immunoreaction 1 week after 
MIA injection (Fig. 2D, 2F).
Finally, histopathological changes and VEGF immuno-
histochemistry were examined in the articular cartilage in the 
guinea pig SPOA model. Examples of young guinea pigs (10 
weeks old) are shown in Fig. 3, panels A and B. In aged guinea 
pigs (16 months old), the articular cartilage became thin and 
included advanced tidemark, chondrocytes were degenerated 
and proteoglycan staining was reduced (Fig. 3C). Fibrillation 
and osteophyte formation were seen in the tibial medial pla-
teau in the frontal plane (data not shown). Moreover, appear-
ance of chondrocyte clones were seen in the destructive carti-
lage matrix (Fig. 3E). Although expression of VEGF was not 
detected in the articular cartilage of young guinea pigs (Fig. 
3B), some regenerative or hypertrophic chondrocytes showed 
positive immunoreaction against VEGF in the articular carti-
lage of aged guinea pigs (Fig. 3D). Moreover, the chondrocyte 
clones showed a strongly positive reaction against VEGF in 
the superficial and middle zone (Fig. 3F).
OA is pathologically characterized by fibrillation and 
erosion in cartilage, by chondrocyte proliferation and os-
teophyte formation at the joint margins and by sclerosis of 
subchondral bone. Destruction of articular cartilage (chon-
drocytes) involving catabolism of matrix proteins of chon-
drocytes, such as type 2 collagen and aggrecan, is caused by 
proteolytic enzymes of the matrix metalloproteinase (MMPs) 
and aggrecanase families. It is also reputed that MMPs or 
MMP13 inhibitors protect cartilage degeneration2–4 and that 
mice deficient in a disintegrin and metalloproteinase with   
thrombospondin motifs 5 (ADAMTS5) and MMP9 are pro-
tected from cartilage damage in some models5,6. Further-
more, other factors such as transforming growth factor-beta 
(TGF-β), cytokines, chemokines and cathepsin have been 
advocated for involvement in OA pathogenesis, but the re-
lationship between these factors and articular cartilage de-
struction is still unknown.
In pathological conditions, such as rheumatoid arthritis 
and OA, damaged articular cartilage is frequently covered 
with and invaded by granulation tissue with high vascular-
ity, the so- called pannus tissue. These findings under patho-
physiological conditions suggest the involvement of angio-
genic factors in the process. Among these, VEGF, which 
is produced by hypertrophic chondrocytes, is considered to 
be a coordinator of extracellular matrix (ECM) remodeling, 
angiogenesis and bone formation in the growth plate22. In 
fact, expression of VEGF was reported in human OA pa-
tients21 and in the rabbit ACLT model23.
In the present study, we found that some regenerative 
chondrocytes, perichondria and clones showed immunore-
action against VEGF in the MIA model, the medial men-
iscectomy model and the SPOA model. We demonstrated 
that expression of VEGF in cartilage was common to three 
different OA models established by different stress mecha-
nisms. Indeed, stain intensity of VEGF was gradually en-
hanced  simultaneously  with  histopathological  severity, 
which was evaluated based on such things as regeneration 
and hypertrophy of the chondrocytes and clones, migration-
al response of perichondrium, as well as osteophyte forma-Yamairi, Utsumi, Fukunari et al. 139
Fig. 1.  Histopathological changes of the articular cartilage of the tibial medial plateau in the frontal plane. The bars indicate 
0.5 mm. A, C, E, G: Toluidine blue staining. B, D, F, H: Immunohistochemical staining of VEGF. A, B: Sham opera-
tion (Control). C, D: One week after the medial meniscectomy. E, F: Two weeks after the medial meniscectomy. G, H: 
Five weeks after the medial meniscectomy. The arrows point to VEGF immunoactivity.OA Models and Expression of VEGF 140
tion and development after articular cartilage destruction. 
Some authors have found that regenerative chondrocytes or 
clones increase with the severity of OA24. The present data 
suggest a possible action of VEGF on the articular chondro-
cytes in OA-like models of rodents.
The primary function of VEGF was supposed to be 
that  of  angiogenesis.  However,  recent  studies  have  dem-
onstrated that the biological function of VEGF is dictated 
mainly by the expression of its receptors on the cells in 
various  tissues  besides  blood  vessels.  Reportedly,  at  the 
cellular level, VEGF did not stimulate the proliferation of 
human OA chondrocytes21. However, VEGF stimulates OA 
chondrocytes to produce increased amounts of MMP-1 and 
MMP-3 without changing the production levels of TIMPs21. 
Fig. 2.  Histopathological changes of the articular cartilage of the femoral condyle after monoiodoacetate (MIA) injection in the frontal 
plane. The bars indicate 200 mm. A, C: Safranin O staining. B, D: Immunohistochemical staining of VEGF. A, B: Saline injec-
tion (Normal). C, D: One week after monoiodoacetate (MIA).Yamairi, Utsumi, Fukunari et al. 141
In animals models, in vivo, regenerative chondrocytes or 
clones subjected to different forms of stress produce VEGF, 
and VEGF may then stimulate OA chondrocytes to produce 
increased MMPs and other proteolytic enzymes for destruc-
tion of articular cartilage.
In conclusion, we demonstrated that VEGF is expressed 
in the articular cartilage of OA-like models of rodents just 
as previously reported in human OA patients. Our data also 
suggest that VEGF is likely to be causally involved in the de-
struction of articular cartilage and in its repair. However, the 
intrinsic functions of VEGF in the pathogenesis of OA re-
main to be elucidated; in particular the localization and speci-
Fig .3.  Histopathological changes of the articular cartilage on age-associated spontaneous OA in guinea pigs. The bars indicate 200 
mm. A, C, E: Safranin O staining. B, D, F: Immunohistochemical staining of VEGF. A, B: 10 weeks old. C, D, E, F: 16 months 
old. A-D: Femoral condyle in the sagittal plane. E, F: Appearance of chondrocyte clones in the cartilage matrix of the tibial 
medial plateau in the sagittal plane.OA Models and Expression of VEGF 142
fication of its subtypes and receptors need to be clarified.
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